Featured Studies

Myelodysplastic syndromes (MDS) are disorders caused by abnormal blood cell production, potentially leading to low cell counts and increased susceptibility to clotting and infections. Past research suggests that inflammation may trigger these abnormalities, and this study seeks to further understand and improve treatment strategies for MDS by investigating the role of inflammation in bone marrow cell development.

Healthy volunteers 18-60 years old are needed to test an investigational drug that was developed to reduce blood pressure in the lungs. The PAH team from @NHLBI hope that this investigational study drug may be helpful in treating patients with PAH in the future.

Researchers are examining genetic and physical characteristics of the small vessel disease called CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarct and leukoencephalopathy). They are enrolling volunteers to serve as healthy controls. Compensation is provided.

Dr. Stephanie Chung and her team at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) are seeking male volunteers aged 18-65 for a study on the impact of low-carb (ketogenic) diets, with or without an investigational dietary supplement called nicotinamide riboside, on energy levels and metabolism during sleep.

The risk of heart disease among African Americans is still common despite a greater understanding of the disease and better approaches to managing it. Healthy cooking and eating patterns can help reduce the risk of heart disease. But things like access to grocery stores and knowledge of good nutrition can affect these healthy patterns. Researchers at The National Institutes of Health want to see if community-based programs can help.

Systemic lupus erythematosus (SLE) creates an imbalance in the innate immune system responsible for chronic inflammation. A study at NHLBI is looking into a Vitamin B supplement, nicotinamide riboside (NR), to see if it improves immune system function in people with SLE. People with SLE will be asked to take the supplement or placebo for 12 weeks. Healthy control subjects will be enrolled to compare baseline blood results but will not take the supplement.

Researchers from the National Cancer Institute at the NIH Clinical Center are currently looking for patients who have HER2-expressing endometrial cancer. The purpose of the study is to test two investigational study drugs, a vaccine that targets HER2 (AdHER2DC) and a drug that is expected to improve immune cell function (N-803). These study drugs will be used with pembrolizumab and lenvatinib which are FDA approved to treat endometrial cancer.

The research study aims to enhance the understanding of SCD and its associated complications by investigating the relationship between the disease and specific variations of certain genes. If you have SCD, your participation in this study is highly valuable. By participating, you will undergo an evaluation and receive recommendations from a team experienced in the treatment and management of SCD.